Surrozen (NASDAQ:SRZNW – Get Free Report) is expected to be posting its resultson Thursday, March 19th. Analysts expect Surrozen to post earnings of ($1.2875) per share and revenue of $0.6610 million for the quarter.
Surrozen Stock Performance
SRZNW opened at $0.02 on Thursday. The stock’s fifty day moving average is $0.02 and its two-hundred day moving average is $0.02. Surrozen has a 52 week low of $0.00 and a 52 week high of $0.05.
About Surrozen
Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.
Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Surrozen
- What a Former CIA Agent Knows About the Coming Collapse
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- The Next Commodity Crunch (bigger than oil?)
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
